Nova Mentis Life Science Corp NMLSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.01–0.01
- 52-Week Range
- $0.01–0.03
- Bid/Ask
- $0.01 / $0.01
- Market Cap
- $1.78 Mil
- Volume/Avg
- 2,000 / 21,978
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 83.08
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company’s goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.novamentis.ca
Valuation
|
Metric
|
NMLSF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 83.08 |
Price/Cash Flow | — |
Price/Earnings
NMLSF
Financial Strength
|
Metric
|
NMLSF
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.03 |
Interest Coverage | — |
Quick Ratio
NMLSF
Profitability
|
Metric
|
NMLSF
|
|---|---|
Return on Assets (Normalized) | −241.12% |
Return on Equity (Normalized) | −1,608.35% |
Return on Invested Capital (Normalized) | −1,768.11% |
Return on Assets
NMLSF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Rclvhjxqf | Nrtf | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lflsmld | Gfbnzh | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cpnmhlgl | Qlwzzr | $118.7 Bil | |||
| Moderna Inc
MRNA
| Ywblgzbz | Bkrtn | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bsqdbtl | Yplvscr | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Gmnmgzcp | Xttr | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Cwhjwjqyn | Szxmm | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ywyqpwgf | Vnqbzsb | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Kxpklkfw | Jbv | $15.0 Bil | |||
| Incyte Corp
INCY
| Zyyydthv | Hgwyyr | $13.5 Bil |